Wellington Management Group LLP Purchases Shares of 457,974 Alamar Biosciences, Inc. $ALMR

Wellington Management Group LLP acquired a new position in Alamar Biosciences, Inc. (NASDAQ:ALMR) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 457,974 shares of the company’s stock, valued at approximately $12,407,000. Wellington Management Group LLP owned 0.66% of Alamar Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Alamar Biosciences Price Performance

Alamar Biosciences stock opened at $30.80 on Tuesday. The firm has a market capitalization of $2.14 billion and a price-to-earnings ratio of -15.71. The business’s fifty day moving average is $28.72. Alamar Biosciences, Inc. has a 52-week low of $18.84 and a 52-week high of $38.54. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03.

Alamar Biosciences (NASDAQ:ALMR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.14. The firm had revenue of $29.43 million during the quarter. On average, equities research analysts predict that Alamar Biosciences, Inc. will post -1.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Leerink Partners assumed coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 price target on the stock. TD Cowen reiterated a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Zacks Research upgraded shares of Alamar Biosciences to a “hold” rating in a research report on Wednesday, May 13th. JPMorgan Chase & Co. upped their price objective on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Finally, Stifel Nicolaus lifted their target price on Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alamar Biosciences currently has an average rating of “Hold” and an average price target of $31.80.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.